Keyword: Cancer Drugs Fund
Pfizer is facing tough competition with Xalkori, and the latest move from England’s cost watchdogs isn’t making things any easier.
Since NICE took the reins of England’s Cancer Drugs Fund last year, several drugmakers have seen their meds get the boot. Not Bayer.
NICE has ruled on a preliminary basis that Merck’s Keytruda isn’t cost effective to treat patients with urothelial carcinoma.
Roche has sealed a deal to provide Gazyvaro to U.K. patients through the revamped Cancer Drugs Fund.
With a full FDA approval granted Friday, AstraZeneca’s lung cancer med Tagrisso is in position to become the standard of care for certain patients with the deadly disease, a company exec predicts.
Merck’s Keytruda is making waves in the U.S. market as a first-line treatment for non-small cell lung cancer. But it won’t be doing so in England—at least not yet.
New cancer drugs are making the grade with England's notoriously tough cost-effectiveness watchdogs. What's changed?
Add Bayer to the list of drugmakers that are feeling the heat from NICE’s Cancer Drugs Fund takeover.
The National Institute for Health and Care Excellence said Wednesday in draft guidance that it wouldn’t recommend Takeda's Adcetris, citing "immature and limited" clinical effectiveness evidence.
Weeks of negotiations with England's cost regulators and health officials have yielded no success in making Lenvima available to thyroid cancer patients, Eisai reported Tuesday as it echoed grievances first aired last month. And the Japanese drugmaker is kicking back.
